Navigation Links
Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
Date:10/16/2007

ee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' business, its partnership strategies, and the future therapeutic and commercial potential of ISIS 369645 and Isis' antisense technologies. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Jellyfish partners for sales tracking technology
4. GE Healthcare partners with UNC on breast cancer imaging research
5. Manufacturing partnership will move into biotech and biomedical spaces
6. Fergus joins Baird Venture Partners, Caden Bio
7. Avolte Venture Partners reaches capital goal
8. NimbleGen partners with UK biotech firm
9. Big pharma seeks Wisconsin biotech partnerships
10. Thompson in partnership to build ethanol plant
11. Johnson Controls partners on car satellite linkup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 Marktech Optoelectronics ... deep ultra violet emitters in the 280 nm wavelength ... UV emitters which range from 280nm to 405nm. These ... water sanitation as well as curing. Mark Campito, Marktech’s ... of special interest to manufacturers is that we offer ...
(Date:9/23/2014)... , September 23, 2014 ... with funding from Imperial Innovations, Cambridge Innovation Capital and ... a clinical cancer genomics company focused on harnessing ... to improve cancer testing and treatment, today announced ... led by Imperial Innovations and including Cambridge Innovation ...
(Date:9/22/2014)... 2014 Research and Markets ... the "Global Biotechnology Reagents Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical compounds ... to detect and examine another substance to provide ... laboratories to prepare, collect, and examine specimens from ...
(Date:9/22/2014)... new star-shaped molecule made up of interlocking rings, which is ... , Known as a ,Star of David, molecule, scientists have ... a century and the team,s findings are published in the ... molecular triangles, entwined about each other three times into a ... is 114 atoms in length around the perimeter. The molecular ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... posts record quarterly revenues of $27.2 million, ... CRY ),a biomaterials, medical device and tissue processing ... of 2008 increased 18 percent to,$27.2 million compared ... 2007.,Excluding orthopaedic tissue processing revenues of $297,000 and ...
... Including Industrial ... ... Bioscience (Nasdaq:,PURE) today announced an agreement with DuraBan International ... DuraBan,s DuraClean(TM) brand., (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ), ...
... Ontario, July 31 TurboSonic,Technologies, Inc. (OTC Bulletin Board: ... industrial air pollution control technologies, today,announced that the company,s ... WallSt.net,s 3-Minute Press Show., The interview gives viewers ... company,s latest press release., To ...
Cached Biology Technology:CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 2CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 3CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 4CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 5CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 6CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 7CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 8CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 9CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 10CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 11PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 3PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 4[video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.net's 3-Minute Press Show 2
(Date:9/22/2014)... and larger areas of sea ice melt in the summer ... it is thinner and more reduced. As the Arctic summers ... warming, because reduced sea ice in the Arctic will remove ... our results are representative, then sea ice plays a greater ... in future global CO2 budgets", says Dorte Haubjerg Sgaard, PhD ...
(Date:9/22/2014)... Boulder, CO, USA More than 7,000 geoscientists will ... papers at The Geological Society of America,s 126th Annual ... will cover such topics as the transportation of crude ... Mars. A dedicated field guide, Trials and Tribulations of ... in and around the Vancouver area. , A broad ...
(Date:9/21/2014)... Calif.) Mothers of children with autism are significantly less ... their pregnancies than the mothers of children who are ... Davis MIND Institute has found. , Low iron intake ... in the child if the mother was 35 or ... if she suffered from metabolic conditions such as obesity ...
Breaking Biology News(10 mins):Arctic sea ice helps remove CO2 from the atmosphere 2Geoscience topics in the spotlight -- Vancouver, BC 2Geoscience topics in the spotlight -- Vancouver, BC 3Geoscience topics in the spotlight -- Vancouver, BC 4Geoscience topics in the spotlight -- Vancouver, BC 5Mothers of children with autism less likely to have taken iron supplements 2
... has been awarded $6.27 million to develop an interactive ... efficient at home. The funding, which covers a two-year ... Advanced Research Projects Agency-Energy (ARPA-E), About $1.28 million in ... the California Energy Commission. The Stanford team will ...
... environmental impact of marine fisheries has caught the eye ... ,ecological risk assessment, (ERA) method have been adopted in ... Pacific, and by the international eco-labelling organisation the Marine ... led by Dr Tony Smith and Dr Alistair Hobday ...
... 150 years ago, he deliberately avoided the subject of the ... ,Creator, in the last paragraph of the book, led us ... matter. An international team, led by Juli Peret of the ... that the British naturalist did explain in other documents how ...
Cached Biology News:Stanford researchers awarded $6.27 million to study energy efficiency and human behavior 2World interest in Australian fishery impact test 2Charles Darwin really did have advanced ideas about the origin of life 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
... Gold® DNA Polymerase is a chemically modified ... chemical moiety is attached to the enzyme, ... the first ramp of thermal cycling (when ... temperatures), the enzyme is inactive. The result ...
Biology Products: